Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

Adam Biczo; Arjun Sahgal; Jorrit Jan Verlaan; Patel Shreyaskumar; Zsolt Szoverfi; Markus Schultheiss; Laurence Rhines; Jeremy Reynolds; Ilya Laufer; Alessandro Gasbarrini; Nicolas Dea; Ziya Gokaslan; Charles Fisher; Chetan Bettegowda; Stefano Boriani; Francis Hornicek; Rory Goodwin; Aron Lazary

doi:10.1177/21925682241227917

Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

Adam Biczo, Arjun Sahgal, Jorrit Jan Verlaan, Patel Shreyaskumar, Zsolt Szoverfi, Markus Schultheiss, Laurence Rhines, Jeremy Reynolds, Ilya Laufer, Alessandro Gasbarrini, Nicolas Dea, Ziya Gokaslan, Charles Fisher, Chetan Bettegowda, Stefano Boriani, Francis Hornicek, Rory Goodwin, Aron Lazary^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

Study Design: Systematic review. Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment. Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov. Results: A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified. Conclusions: There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.

Original language	English
Pages (from-to)	120S-131S
Journal	Global Spine Journal
Volume	15
Issue number	1_suppl
DOIs	https://doi.org/10.1177/21925682241227917
Publication status	Published - Jan 2025

Keywords

chondrosarcoma
chordoma
malignant tumor
oncology
spine
targeted therapy

Access to Document

10.1177/21925682241227917Licence: CC BY-NC-ND

biczo-et-al-2025-latest-developments-in-targeted-biological-therapies-in-the-management-of-chordoma-and-chondrosarcomaFinal published version, 771 KBLicence: CC BY-NC-ND

Cite this

Biczo, A., Sahgal, A., Verlaan, J. J., Shreyaskumar, P., Szoverfi, Z., Schultheiss, M., Rhines, L., Reynolds, J., Laufer, I., Gasbarrini, A., Dea, N., Gokaslan, Z., Fisher, C., Bettegowda, C., Boriani, S., Hornicek, F., Goodwin, R., & Lazary, A. (2025). Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma. Global Spine Journal, 15(1_suppl), 120S-131S. https://doi.org/10.1177/21925682241227917

@article{3030cfada082448c831fe01c7fff1e8d,

title = "Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma",

abstract = "Study Design: Systematic review. Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment. Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov. Results: A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified. Conclusions: There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.",

keywords = "chondrosarcoma, chordoma, malignant tumor, oncology, spine, targeted therapy",

author = "Adam Biczo and Arjun Sahgal and Verlaan, \{Jorrit Jan\} and Patel Shreyaskumar and Zsolt Szoverfi and Markus Schultheiss and Laurence Rhines and Jeremy Reynolds and Ilya Laufer and Alessandro Gasbarrini and Nicolas Dea and Ziya Gokaslan and Charles Fisher and Chetan Bettegowda and Stefano Boriani and Francis Hornicek and Rory Goodwin and Aron Lazary",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = jan,

doi = "10.1177/21925682241227917",

language = "English",

volume = "15",

pages = "120S--131S",

journal = "Global Spine Journal",

issn = "2192-5682",

publisher = "SAGE Publications Inc.",

number = "1\_suppl",

}

Biczo, A, Sahgal, A, Verlaan, JJ, Shreyaskumar, P, Szoverfi, Z, Schultheiss, M, Rhines, L, Reynolds, J, Laufer, I, Gasbarrini, A, Dea, N, Gokaslan, Z, Fisher, C, Bettegowda, C, Boriani, S, Hornicek, F, Goodwin, R & Lazary, A 2025, 'Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma', Global Spine Journal, vol. 15, no. 1_suppl, pp. 120S-131S. https://doi.org/10.1177/21925682241227917

TY - JOUR

T1 - Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

AU - Biczo, Adam

AU - Sahgal, Arjun

AU - Verlaan, Jorrit Jan

AU - Shreyaskumar, Patel

AU - Szoverfi, Zsolt

AU - Schultheiss, Markus

AU - Rhines, Laurence

AU - Reynolds, Jeremy

AU - Laufer, Ilya

AU - Gasbarrini, Alessandro

AU - Dea, Nicolas

AU - Gokaslan, Ziya

AU - Fisher, Charles

AU - Bettegowda, Chetan

AU - Boriani, Stefano

AU - Hornicek, Francis

AU - Goodwin, Rory

AU - Lazary, Aron

PY - 2025/1

Y1 - 2025/1

N2 - Study Design: Systematic review. Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment. Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov. Results: A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified. Conclusions: There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.

AB - Study Design: Systematic review. Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment. Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov. Results: A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified. Conclusions: There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.

KW - chondrosarcoma

KW - chordoma

KW - malignant tumor

KW - oncology

KW - spine

KW - targeted therapy

UR - https://www.scopus.com/pages/publications/85215685750

U2 - 10.1177/21925682241227917

DO - 10.1177/21925682241227917

M3 - Article

AN - SCOPUS:85215685750

SN - 2192-5682

VL - 15

SP - 120S-131S

JO - Global Spine Journal

JF - Global Spine Journal

IS - 1_suppl

ER -

Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this